Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

LONDON, Nov. 23, 2018 /PRNewswire/ -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission.  The annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com



Investor contact:



International Media Contact:



U.S. Media Contact:  

S.A. Noonan Communications



JW Communications



Rx Communications Group, LLC

Susan A. Noonan



Julia Wilson



Paula Schwartz

+1-212-966-3650



+44 (0)7818 430877



+ 1-917-322-2216

susan@sanoonan.com



juliawilsonuk@gmail.com



pschwartz@rxir.com





















 



Cision View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-submits-fiscal-year-2018-form-20-f-300754699.html

SOURCE Autolus Therapeutics plc

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!